Last update 21 Oct 2025

GPC2 CAR-T cell therapy (Childrens Hospital of Philadelphia/Tmunity Therapeutics)

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
GPC2 CAR Tcell therapy, GPC2 CAR Tcell therapy Tmunity Therapeutics, GPC2 chimeric antigen receptor Tcell therapy
+ [1]
Target
GPC2
Action
inhibitors
Mechanism
GPC2 inhibitors(glypican 2 inhibitors), Gene transference(Gene transference), T lymphocyte replacements
Therapeutic Areas
NeoplasmsCongenital DisordersEye Diseases+ [2]
Active Indication
High Risk NeuroblastomaNeuroblastoma recurrentRefractory Neuroblastoma+ [3]
Inactive Indication-
Originator Organization
The Children's Hospital of PhiladelphiaThe Children's Hospital of Philadelphia
Active Organization
Gilead Sciences, Inc.Gilead Sciences, Inc.The Children's Hospital of PhiladelphiaThe Children's Hospital of PhiladelphiaTmunity Therapeutics, Inc.Tmunity Therapeutics, Inc.
Inactive Organization-
License Organization
The Children's Hospital of PhiladelphiaThe Children's Hospital of PhiladelphiaTmunity Therapeutics, Inc.Tmunity Therapeutics, Inc.
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with GPC2 CAR-T cell therapy (Childrens Hospital of Philadelphia/Tmunity Therapeutics)
NCT05650749
/ RecruitingPhase 1IIT
Phase 1 Trial of GPC2-Directed Chimeric Antigen Receptor Autologous T Cells (GPC2 CAR T) for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
100 Clinical Results associated with GPC2 CAR-T cell therapy (Childrens Hospital of Philadelphia/Tmunity Therapeutics)
Login to view more data
100 Translational Medicine associated with GPC2 CAR-T cell therapy (Childrens Hospital of Philadelphia/Tmunity Therapeutics)
Login to view more data
100 Patents (Medical) associated with GPC2 CAR-T cell therapy (Childrens Hospital of Philadelphia/Tmunity Therapeutics)
Login to view more data
100 Deals associated with GPC2 CAR-T cell therapy (Childrens Hospital of Philadelphia/Tmunity Therapeutics)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
High Risk NeuroblastomaPhase 1
United States
Gilead Sciences, Inc.Gilead Sciences, Inc.
23 May 2023
High Risk NeuroblastomaPhase 1
United States
The Children's Hospital of PhiladelphiaThe Children's Hospital of Philadelphia
23 May 2023
Neuroblastoma recurrentPhase 1
United States
Gilead Sciences, Inc.Gilead Sciences, Inc.
23 May 2023
Neuroblastoma recurrentPhase 1
United States
The Children's Hospital of PhiladelphiaThe Children's Hospital of Philadelphia
23 May 2023
Refractory NeuroblastomaPhase 1
United States
The Children's Hospital of PhiladelphiaThe Children's Hospital of Philadelphia
23 May 2023
Refractory NeuroblastomaPhase 1
United States
Gilead Sciences, Inc.Gilead Sciences, Inc.
23 May 2023
RetinoblastomaPhase 1
United States
Gilead Sciences, Inc.Gilead Sciences, Inc.
23 May 2023
RetinoblastomaPhase 1
United States
The Children's Hospital of PhiladelphiaThe Children's Hospital of Philadelphia
23 May 2023
NeuroblastomaPreclinical
United States
Tmunity Therapeutics, Inc.Tmunity Therapeutics, Inc.
-
Small Cell Lung CancerPreclinical
United States
Tmunity Therapeutics, Inc.Tmunity Therapeutics, Inc.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free